TWI737974B - 用於治療增生性失調的劑量方案 - Google Patents

用於治療增生性失調的劑量方案 Download PDF

Info

Publication number
TWI737974B
TWI737974B TW108110582A TW108110582A TWI737974B TW I737974 B TWI737974 B TW I737974B TW 108110582 A TW108110582 A TW 108110582A TW 108110582 A TW108110582 A TW 108110582A TW I737974 B TWI737974 B TW I737974B
Authority
TW
Taiwan
Prior art keywords
curcumin
dmpc
dmpg
cancer
dose
Prior art date
Application number
TW108110582A
Other languages
English (en)
Chinese (zh)
Other versions
TW201946613A (zh
Inventor
彼德 索迪羅
Original Assignee
美商標徑製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商標徑製藥公司 filed Critical 美商標徑製藥公司
Publication of TW201946613A publication Critical patent/TW201946613A/zh
Application granted granted Critical
Publication of TWI737974B publication Critical patent/TWI737974B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108110582A 2018-04-09 2019-03-27 用於治療增生性失調的劑量方案 TWI737974B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
US62/655,095 2018-04-09

Publications (2)

Publication Number Publication Date
TW201946613A TW201946613A (zh) 2019-12-16
TWI737974B true TWI737974B (zh) 2021-09-01

Family

ID=68164516

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108110582A TWI737974B (zh) 2018-04-09 2019-03-27 用於治療增生性失調的劑量方案

Country Status (11)

Country Link
US (2) US11813356B2 (https=)
EP (1) EP3773529B1 (https=)
JP (2) JP7241426B2 (https=)
KR (2) KR20240027843A (https=)
CN (1) CN112272555A (https=)
AU (1) AU2019250832B2 (https=)
CA (1) CA3096591C (https=)
ES (1) ES3061642T3 (https=)
MX (1) MX2020010651A (https=)
TW (1) TWI737974B (https=)
WO (1) WO2019199469A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A1 (en) 2023-02-28 2026-01-07 Panasonic Intellectual Property Management Co., Ltd. Non-aqueous electrolyte secondary battery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
PT2146721E (pt) 2007-05-15 2013-07-18 Otsuka Pharma Co Ltd Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência
CN101766619B (zh) * 2008-12-30 2011-08-24 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
EP2501372A4 (en) * 2009-11-19 2013-04-10 Signpath Pharma Inc INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER
US9170257B2 (en) 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
DE112013004278T5 (de) * 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
JP6895252B2 (ja) * 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Also Published As

Publication number Publication date
ES3061642T3 (en) 2026-04-06
CA3096591C (en) 2023-06-27
JP7241426B2 (ja) 2023-03-17
US20240050372A1 (en) 2024-02-15
AU2019250832B2 (en) 2022-10-27
CN112272555A (zh) 2021-01-26
US11813356B2 (en) 2023-11-14
EP3773529C0 (en) 2025-12-24
EP3773529A1 (en) 2021-02-17
EP3773529B1 (en) 2025-12-24
JP2023030106A (ja) 2023-03-07
KR102637598B1 (ko) 2024-02-16
AU2019250832A1 (en) 2020-10-29
JP2021521130A (ja) 2021-08-26
WO2019199469A1 (en) 2019-10-17
TW201946613A (zh) 2019-12-16
KR20240027843A (ko) 2024-03-04
US12551436B2 (en) 2026-02-17
KR20200141062A (ko) 2020-12-17
US20210161815A1 (en) 2021-06-03
EP3773529A4 (en) 2021-12-22
MX2020010651A (es) 2021-01-15
CA3096591A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
Dong et al. Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein
JP6861682B2 (ja) コエンザイムＱ１０（ＣｏＱ１０）の静脈内投与用製剤およびその使用方法
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
CN103221040B (zh) 双硫仑制剂及用途
US20080103213A1 (en) Liposomal curcumin for treatment of neurofibromatosis
CN105338973A (zh) 使用辅酶q10联合疗法治疗癌症
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
US12551436B2 (en) Dosing regimens for treatment of proliferative disorders
JP7596323B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
US12303513B2 (en) Methods and compositions to treat cancer
TW202216122A (zh) 微脂體製劑
US20150147385A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
HK40044373A (en) Dosing regimens for treatment of proliferative disorders
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
Wu et al. Chemotherapy-photothermal liposomes modified by DNA-protein network inhibit oral squamous cell carcinoma progression basing on regulating tumor microenvironment
WO2020023436A1 (en) Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
EP3071190A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
HK1130659A (en) Methods of treating influenza viral infections